)
Level Bio (LEVBIO) investor relations material
Level Bio Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue rose 28% YoY to 8,644 KSEK; comparable growth excluding CyberGene was 59%, while gross margin fell to 40%.
Techtum Lab drove growth; priorities include Nordic expansion, portfolio development and profitability.
Financial highlights
Q3 revenue was 8,644 KSEK vs 6,750 KSEK; excluding CyberGene’s prior-year contribution, sales were 8,644 KSEK vs 5,432 KSEK, up 59%.
Q3 gross profit was 3,415 KSEK vs 3,787 KSEK; operating loss was 310 KSEK vs 207 KSEK, and net loss was 348 KSEK vs 164 KSEK.
9M revenue rose 17% to 26,841 KSEK from 22,939 KSEK; growth was 31% excluding CyberGene. Gross profit was 12,452 KSEK.
9M operating loss narrowed to 652 KSEK from 2,599 KSEK; result after financial items was 5,684 KSEK vs a loss of 2,649 KSEK, impacted by the disposal.
Q3 cash flow was -11 KSEK vs +16 KSEK YoY; 9M cash flow was -2,418 KSEK vs +496 KSEK.
Outlook and guidance
Strategy centers on Techtum Lab as a platform for profitable growth, growing distribution sales and reaching profitability.
Plans include establishing local presence across Nordic countries through hiring and/or acquisitions, and expanding sales in all Nordic markets.
Q4 priorities are sales execution, Nordic expansion and profitability; portfolio and pricing decisions will balance growth with margin.
CyberGene’s divestment creates comparison effects expected to persist through Q1 2027.
- Q2 2026 saw 10% sales growth and a major capital gain from the CyberGene divestment.LEVBIO
Q2 2026 - 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution.LEVBIO
Q1 2026 - 29% revenue growth and CyberGene sale mark a strategic shift to Nordic lab distribution.LEVBIO
Q4 2025 - Q3 2025 saw 5% revenue growth, higher margins, and improved cash flow amid Nordic expansion.LEVBIO
Q3 2025 - Strong revenue growth, improved margins, and positive cash flow signal ongoing turnaround.LEVBIO
Q2 2025 - Flat sales but improved results and cash flow signal operational progress and future growth.LEVBIO
Q3 2024 - Q2 sales grew 10% year-over-year, with H2 growth expected from new products.LEVBIO
Q2 2024 - Strong 42% revenue growth and positive cash flow signal operational turnaround.LEVBIO
Q1 2025 - Q4 revenue up 22% and gross margin at 58%, with recurring sales driving future growth.LEVBIO
Q4 2024
)
)
)
)
)
)
)
)